OBJECTIVE:To compare the dissolution rates of levofloxacin tablets produced in 4 domestic pharmaceutical manufacturers in order to provide the evidence for its clinical use.METHODS:UV spectrohpotmetry was used to determine the cumulative dissolution rates of these 4 kinds of levofloxacin tablets at different time points,the dissolution parameters of T50,Td,T80,and M were calculated by Weibull formula,then variance analysis was made.RESULTS:The dissolution rates of these 4 kinds of levofloxacin tablets all met the standards recorded in 2000 edition of China Pharmacopoeia,but significant differences were found in parameters of T50,Td,T80,and M(P

Objective To investigate the correlation of long term aspirin treatment and cerebral microbleeds(CMBs)incidence in non-hypertensive patients.Methods 56 non-hypertensive patients (the average age of 64.88±6.99)with long term aspirin adminis-tration (100 mg/d)were enrolled in the study from 2005 to 2010 in our hospital,with follow up to compare CMBs 5-10 years later. All patients underwent T2 WI,T1 WI,diffusion-weighted imaging (DWI)and susceptibility weighted imaging (SWI).The CMBs lesions were defined by senior radiologists.Patients’age,gender,total cholesterol level,aspirin,CMBs and CMBs location were taken into account in data analysis.Results CMBs incidence was 14.3% in all participants,lesions were located mostly in lobes.Aged,male and low total cholesterol level were the risk factors of CMBs (P<0.05).Patients with CMBs were more likely to suffer from acute cere-bral infarction (P<0.05).Two of 56 patients with new CMBs lesions located in lobar and mixed location respectively only.Conclusion Long term aspirin administration does not increase the risk of CMBs in non-hypertensive patients(P>0.05),the potential adverse effect of aspirin needs further investigation.

OBJECTIVE:To study the quality standard of compound polysaccharide selenate capsules(CPSC).METHODS:Astragalus and oldenlandia were identified by TLC method and the content of selenium in CPSC was determined by fluo?rospectrophotometry.RESULTS:Linear range was0～0.5?g/ml and average recovery was100.4%,RSD=0.91%(n=5). CONCLUSION:This method is simple and accurate,and can be used for quality control of CPSC.

In this study,we constructed 2 eukaryotic expressing plasmids namely pcS2?S and pFP,encoding HBV preS2+S envelope protein and human IL 2/IFN ? fusion protein, respectively. The double plasmid fusion protein was used as an adjuvant in preparation of a treatment type HBV gene vaccine. To investigate its feasibility for use as a therapeutic DNA vaccine, we've evaluated the immune response after injection into healthy mice, HBV transgenic(Tg) mice, New Zealand rabbits and Rhesus monkeys. The results showed that the therapeutic DNA vaccine can improve: (1)the CTL activity; (2)the HBsAg(30?g/ml) specific T lymphocyte proliferation in which the stimulation index(SI) and cytokines(IL 2/IFN r) release levels of the pS2.S immunized group(SI=5.6?0.9; 226.3?41.1/51.1?7.1pg/ml) were significantly higher( P

The peptides from HBV cytotoxic T lymphocyte(CTL) epitope were used to either stimulate or impact the immune effector (E) or CTL target (T) cells respectively, in order to investigate the cellular immune response induced by DNA vaccination in both healthy and HBV transgenic (Tg) mice. It was found that HBV DNA based immunization could induce CTL activity in healthy BALB/c mice, with intensity correlated with the E/T ratio and IFN ? secretion level in its supernatants. The target cells hit by HBsAg CTL epitope peptide(pp20) could be lysed by the active CTL induced by HBV DNA vaccine encoding preS2 and HBsAg, while the cell lysis could not be observed in the target cells impacted by the HBcAg CTL epitope peptide (pp10). The supernatant IL 12 secretion level (211 3?39 8pg?ml -1 ) in the DNA vaccination group was significantly( P

To develop an effective therapeutic HBV DNA vaccine, two eukaryotic expressing plasmids, namely pcDNAS 2 ?S and pcDNAIIF , which respectively encoding HBV middle envelope protein preS 2 ?S and human IL 2/IFN ? fusion protein, were constructed by DNA recombinant technique. After identification by restriction analysis and DNA sequencing, the constructed recombinant plasmids were transfected into COS 7 cells in vitro with transfection reagent Lipofectamine. The expressed product in supernatant was quantified by ELISA , and the biologic activities of IL 2 and IFN ? were assayed by CTLL 2 cell line proliferation and cytopathogenic inhibition, respectively. The results showed that secretive expression of preS 2 ?S and hIL 2/hIFN ? fusion protein peaked at 48h after transfection, and the expression levels were HBsAg(P/N)=7 63, IL 2=10 35ng/ml, and IFN ?=7 90ng/ml. The IL 2 and IFN ? activities in the culture supernatant of COS 7 cells transfected with pcDNAIIF were 998U/ml and 249U/ml, respectively. These results suggested that the recombinant plasmids pcDNAS 2 ?S and pcDNAIIF were correctly constructed and the transfected cells could express secretive active protein.

OBJECTIVE:To develop a HPLC assay for the determination of 7 kinds of amino acids in amino acid capsules by using online derivation and diode array detector.METHODS:The high performance chromatograph of liquid with the device of automatic derivation was employed as the automatic sampler.The samples were injected in the predefined procedure,and detected with the diode array detector.RESULTS:Good resolution of 7 kinds of amino acids was obtained,and the respective detectable concentration showed a good linear relationship with its peak area.CONCLUSION:The present method is convenient,well reproduced, highly sensitive,and accurate,therefore it can be widely used.

Objective:To investigate the feasibility and its action of the therapeutic DNA vaccine for treatment of HBV infection.Methods:By genetic recombinant technique,have constructed 2 eukaryotic expressing plasmids namely pS2.S and pFP,encoding HBV envelope middle protein(preS2+HBsAg) and human leukocyte cytokines fusion protein(IL 2/IFN ?) genes respectively and evaluated its efficacy for inducing cellular immunity in healthy BALB/c mice and HBsAg serum conversion in HBV transgenic(Tg) mice after immunization of the plasmids by intramuscular administration.Results:1.The T cell proliferation by in vitro HBsAg stimulation closely correlated with HBsAg concentration,with its stimulation index(SI=5.6?0.9) in pS2.S immunized group,being significantly higher than that (2.0?0.5) of the control.The IL 2 and IFN ? secretion level in supernatant of the DNA vaccine immunized spleen cell culture were significantly higher than that of the control,while the IL 4 secretion level was not affected.2.The dendritic cells(DCs) extracted from the local draining lymph node(LN) after DNA vaccination induced a HBsAg specific T cell proliferation with its SI(4.20) being higher than that(2.55) of the control.3.In each group of high dose pS2.S and the middle dose combined with pFP inoculation,the HBsAg serum conversion occurred in one HBV Tg mouse,with the serum anti HBs level increasing as the time prolonged,while the serum HBsAg level of the rest mice were significantly lower than that of the control.Conclusion:The results suggest that HBV DNA vaccine can effectively induced cellular immunity in healthy mice;and the preliminary results of the immunized HBV Tg mice may provide an experimental evidence for further investigation of DNA vaccine for its use in treatment of HBV infection.

Objective:To investigate the application value of serum procalcitonin in patients with viral infection,bacterial infection and severe bacterial infection.Methods:Selected60 cases of patients with infection who were treated in our hospital from June 2014toDecember 2016,divided into three groupsaccording to the severity of the infection,viral infection (group A) 15 cases,general bacterial infection (group B) 22 cases,and severe bacterial infection (group C) 23 cases.Three groups of patients were treated with symptomatic treatment,and after admission,the serum procalciton in levels were detected in 1,3,5,7 d,and compared with the serum procalcitonin levels before and after treatment in the three groups.Results:The serum procalcitonin ≥ 0.5 μg/L number of B group and C group had no significant difference (P＞0.05),the serum procalcitonin ≥ 0.5 μg/L number of A group was significantly lower than that of B group and C group (P＜0.05);the survival rate of severe bacterial infection patients whose serum procalcitonin was higher than than 0.5 μg/L was significantly higher than those who with serum procalcitonin lower than 0.5 μg/L (P＜0.05).Conclusion:Serumprocalcitonin level had a good application value in the clinical diagnosis prognostic prediction of patients with severe infection.